SAN DIEGO, Sept. 29, 2022 (GLOBE NEWSWIRE) — aTyr Pharma, Inc. LIFE, a biotherapeutics company engaged in the discovery and development of first-in-class drugs based on its proprietary tRNA synthetase platform, announced today that the United States Patent and Trademark Office (USPTO) has issued a statement of approval for a patent covering methods of using anti-neuropilin-2 (NRP2) antibodies. Patent Application No. 16/376,979 entitled “Compositions and Methods Comprising Anti-NRP2 Antibodies” involves the use of a panel of antibodies that target NRP2 for differentiated therapeutic applications in the areas of cancer and inflammation.

NRP2 is a cell surface receptor that plays multiple roles in neurodevelopment by maintaining cellular plasticity, cell migration, lymphatic development, and regulating inflammatory responses in normal physiology. The blocking antibodies aTyr has developed target specific domains of NRP2, including those that interact with semaphorins, VEGF and certain chemokines.

“We are pleased to receive USPTO acceptance letters for this patent, which covers compositions and methods involving anti-NRP2 antibodies, including our IND candidate ATYR2810, the first patent granted to our intellectual property for this program,” said Sanjay S. Shukla, MD, MS, President and Chief Executive Officer of aTyr.

A notice of grant is issued after the USPTO has determined that a patent should be granted based on an application. A patent from the recently approved application is expected to be granted in the coming months.

aTyr’s global patent portfolio includes over 220 granted or permitted patents owned or exclusively licensed by aTyr and its Hong Kong subsidiary, Pangu BioPharma Limited, and developed over a decade of research and development activities. This patent ownership underscores aTyr’s unique leadership position in this emerging area of ??biology. These patents covered important new therapeutic modalities that…

Read full story here